Eyenovia is a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications. Co.'s drug-device therapeutic programs include MicroPine, MicroLine and Mydcombi™. MicroPine is Co.'s topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. MicroLine is Co.'s investigational pharmacologic treatment for presbyopia. Mydcombi™ is Co.'s fixed combination formulation of tropicamide-phenylephrine for mydriasis.